Graeme Roy Kaufman
Plus aucun poste en cours
Profil
Graeme Roy Kaufman served as the Chief Financial Officer of CSL Ltd.
from 1984 to 1999.
He was also an Executive Director of Opthea Ltd.
from 2002 to 2007.
Kaufman held several non-executive chairman and director positions in various firms such as Bionomics Ltd., Paradigm Biopharmaceuticals Ltd., Anagenics Ltd., and Idt Australia Ltd.
He was also an Executive Vice President-Finance at Mesoblast Ltd.
Kaufman obtained his undergraduate degree and MBA from the University of Melbourne.
Anciens postes connus de Graeme Roy Kaufman
| Sociétés | Poste | Fin |
|---|---|---|
| PARADIGM BIOPHARMACEUTICALS LIMITED | Président | 24/06/2020 |
| IDT AUSTRALIA LIMITED | Président | 21/11/2017 |
| BIONOMICS LIMITED | Président | 08/11/2016 |
| ANAGENICS LIMITED | Directeur/Membre du Conseil | 30/06/2015 |
| MESOBLAST LIMITED | Corporate Officer/Principal | 01/01/2013 |
Formation de Graeme Roy Kaufman
| University of Melbourne | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| OPTHEA LIMITED | Health Technology |
| CSL LIMITED | Health Technology |
| ANAGENICS LIMITED | Consumer Non-Durables |
| BIONOMICS LIMITED | Health Technology |
| IDT AUSTRALIA LIMITED | Health Technology |
| PARADIGM BIOPHARMACEUTICALS LIMITED | Health Technology |
| MESOBLAST LIMITED | Health Technology |
| Entreprise privées | 1 |
|---|---|
CSL Innovation Pty Ltd.
 CSL Innovation Pty Ltd. Pharmaceuticals: MajorHealth Technology CSL Innovation Pty Ltd. develops pharmaceutical products. The firm also develops human antibody inhibitors of the granulocyte-macrophage colony stimulating factor receptor alpha subunit, GM-CSFRa, for potential therapeutic use in inflammatory diseases. The company was founded in 1986 and is headquartered in Richmond, Australia. | Health Technology |
